COMP <GO>
ABBV vs PM // FORWARD P/E MULTIPLE
AbbVie Inc. (NYSE) VS. Philip Morris International Inc (NYSE) • 15-METRIC TALLY: ABBV 7
— PM 7
▲ FORWARD P/E MULTIPLE LEADER: PM
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
forward-pe
113.1x
LAST: $208.50 (+2.89%) • MKT CAP: $324.98B
forward-pe
26.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABBV VS. PM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABBV | PM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 70.20% | 67.10% | +3.10 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.00% | 45.30% | -16.30 | PM | /roic <GO> |
| EV/EBITDA & P/E Valuation | 33.3x | 21.7x | +11.60 | PM | /valuation <GO> |
| Free Cash Flow Yield | 3.47% | 3.28% | +0.19 | ABBV | /fcf-yield <GO> |
| Operating Margin | 24.60% | 36.60% | -12.00 | PM | /operating-margins <GO> |
| Net Profit Margin | 6.90% | 27.90% | -21.00 | PM | /net-margins <GO> |
| Revenue Growth (YoY) | 8.60% | 7.30% | +1.30 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.27% | 2.65% | -0.38 | PM | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.33 | 4.52 | +0.81 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | PM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.1 | 63.9 | +1.20 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.93 | +0.22 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 113.1x | 26.6x | +86.50 | PM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $513.86B | $324.98B | $188.88B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABBV REV | PM REV | ABBV GROSS % | PM GROSS % | ABBV FCF | PM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $61.16B | $40.65B | 70.2% | 67.1% | $17.82B | $10.66B |
| FY 2024 | $56.33B | $37.88B | 70.0% | 64.8% | $17.83B | $10.77B |
| FY 2023 | $54.32B | $35.17B | — | — | $20.39B | $7.62B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABBV // BETA 1.15
PM // BETA 0.93